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Abstract Many tumorigenic p53 mutants gain a common anti-
genic epitope that is recognized by the PAb-240 antibody. Data-
base search identi¢ed the presence of this epitope in several
other proteins, including several antibodies and the catalytic
subunit of mouse telomerase, mTERT. These antibodies may
represent a part of the previously demonstrated anti-idiotypic
network built around p53. In the present study we demonstrate
that the PAb-240 antibody was able to inhibit telomerase activ-
ity in extracts from both mouse and human tumor cells. The
recognition of mTERT by PAb-240 is demonstrated by Western
blotting and by using blocking peptides derived from mTERT.
The existence of a shared epitope between mutant p53 and
telomerase may suggest that the two proteins contribute to ma-
lignant transformation through a common pathway.
+ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
It is well accepted that inactivation of the p53 tumor sup-
pressor gene plays a central role in the induction and progres-
sion of malignant transformation [1]. Tumorigenic mutations
in the p53 gene occur at a high frequency mostly at the core
domain of the molecule [2]. The majority of mutations in p53
are missense, and result in a full length, albeit mutant, pro-
tein. The observation that a high percentage of primary tu-
mors overexpress various forms of mutant p53 implies that its
presence may confer some selective advantage to cancer cells.
It was suggested that mutant p53 might act by a dominant
negative mechanism or by gain of function. The possibility
that mutant p53 acts by gain of function was mostly based
on the observation that transfection of mutant p53 into p53
null cells conferred a more highly malignant phenotype. Re-
cent studies have suggested that mutant p53 function is asso-
ciated with transcriptional activity [3] ; however, the molecular
mechanisms and the pathways associated with the oncogenic
gain of function of p53 mutants are still unknown [4,5].
The integrity of the protein conformation of wild type p53
is central for its activity. Although tumorigenic mutations
occur at various parts of the molecule, many of them gain a
common antigenic epitope that is recognized by the PAb-240
anti-p53 monoclonal antibody [6]. The PAb-240 linear epitope
spans ¢ve amino acids that are located at the middle of the
central core domain of p53 (amino acids 213^217) and is in-
accessible to the antibody in the wild type p53 conformation
[7]. It was assumed that many mutations cause partial unfold-
ing of the core domain leading to the exposure of this epitope.
Thus, the PAb-240 epitope is considered to be mutant speci¢c
[6]. The existence of a common mutant speci¢c epitope may
imply that the various mutant p53 forms share a speci¢c con-
formational structure that is important for their malignancy
associated activity. If indeed mutant p53 acts by gain of func-
tion, then one possible mechanism that may underlie its ac-
tivity could be that the PAb-240 antigenic epitope is also
shared by other cellular protein(s). Once mutant p53 is over-
produced in tumor cells it may modulate the regulation
of important growth control pathways. This hypothesis
prompted us to conduct a database search for cellular proteins
which may express the PAb-240 antigenic epitope.
2. Materials and methods
2.1. Blocking of PAb-240 by peptides derived from human or mouse
TERT
PAb-240 antibody was preincubated either with 200 Wg of peptides
1, 2, 3, 4 or with 40 Wg of peptides 5, 6, and 7 (Fig. 1A) for 1 h at
room temperature. Eight identical samples each containing 1 Wg of
baculoviral derived p53 protein were separated by 10% sodium do-
decyl sulfate^polyacrylamide gel electrophoresis (SDS^PAGE). After
transfer to nitrocellulose membrane lanes were excised and reacted
with the PAb-240 antibody, preincubated with the indicated peptides.
The protein^antibody complexes were detected by a horseradish per-
oxidase (HRP)-conjugated secondary antibody (Boehringer Mann-
heim) using the enhanced chemiluminescence system (Amersham).
2.2. Telomerase activity assays
Telomerase activity determinations were performed using a com-
mercial TRAPeze kit (Intergene) according to the manufacturer’s
non-radioactive protocol. However, the cycling conditions were modi-
¢ed as follows: 30‡C 30 min, 94‡C 3 min, and 29 cycles of ampli¢-
cation: 94‡C for 30 s, 56‡C for 30 s, 72‡C for 30 s. 200 ng lysate per
TRAP reaction was used.
For the immunodepletion assays, 20 Wg of cell lysates prepared
according to the TRAPeze kit instructions was incubated with either
PAb-240 or PAb-421 antibodies overnight in 150 Wl IP bu¡er (50 mM
Tris pH 8, 5 mM EDTA, 150 mM NaCl, 0.5% NP-40 and a protease
inhibitor cocktail (Roche)). Then, aliquots were taken and 2 Wl was
used in TRAP assay (designated binding). 30 Wl of protein A beads
was added to the rest. After 2 h rolling at 4‡C and centrifugation the
supernatant was removed and 2 Wl was used for the TRAP assay
(designated immunodepletion).
2.3. Western blot analysis
For Western blotting of TERT protein, 100 Wg of nuclear extracts
prepared according to Dignam [8] was separated by 7.5% SDS^PAGE
and transferred to nitrocellulose membrane. Membranes were blocked
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overnight with 5% dry skimmed milk in phosphate bu¡ered saline^
Tween (PBST) and TERT protein was detected using either commer-
cial anti-TERT polyclonal antibody (Calbiochem, Cat. No. 581400)
diluted 1:500 in 5% milk^PBST or PAb-240. The protein^antibody
complexes were detected using an HRP-conjugated secondary anti-
body (Boehringer Mannheim) by enhanced chemiluminescence system
(Amersham).
3. Results and discussion
The non-redundant GenBank database was searched for
mammalian proteins containing the amino acid sequence
RHSVV (PAb-240 epitope) [7] using the BLASTP 2.2.3 pro-
gram for short nearly exact matches [9]. Table 1 presents all
perfect matches obtained from such a Blast search. It should
be noted that the PAb-240 epitope is highly conserved in p53
orthologs and therefore those were not included in this table.
The data obtained by our search can be divided into three
main categories.
The ¢rst category identi¢ed in our Blast search consists of
hypothetical proteins and proteins with unknown function.
The signi¢cance of sharing the PAb-240 epitope with p53 by
these proteins will be resolved once their function is under-
stood. The fact that so many cellular proteins share this anti-
genic epitope emphasizes the problematics of using PAb-240
monoclonal antibody as a single reagent for the identi¢cation
of p53.
The second category of proteins identi¢ed in our search
consists of 17 hits of mouse antibodies that contain the
PAb-240 epitope sequence in their variable regions. In his
idiotypic network theory Jerne [10] suggested that a given
antibody (Ab1) does not only react with an epitope on a
target antigen, but that it is also subject to recognition itself.
Thus, Ab1 may induce other, anti-idiotypic antibodies (Ab2),
some of which could mimic the antigenic determinant recog-
nized by Ab1. The idiotype of Ab2 also can be recognized by
a set of antibodies (Ab3), of which some may again manifest
the speci¢city of Ab1.
Indeed, it was shown previously that mice immunized with
Ab1 PAb-240 spontaneously produce Ab3 anti-p53 antibodies
that re£ect the speci¢city of their Ab1 inducer; PAb-240 in-
duced Ab3 speci¢c for mutant p53. This study suggested that
an anti-idiotypic network built around certain domains of p53
seems to be programmed within the immune system and can
be associated with the resistance of the host to tumor develop-
ment [11,12]. It is possible that some of the antibodies iden-
ti¢ed in our search represent the Ab2 antibodies, which can
mimic the DNA binding domain of p53.
The third category consists of known characterized proteins
that include the mouse transcription factor IIIA that was al-
ready predicted to contain the PAb-240 epitope [7]. Another
interesting member identi¢ed in this category is the catalytic
subunit of telomerase. Since both p53 and telomerase are in-
volved in malignant transformation we have further focused
in this report on the possible relationship between the two.
Telomerase, a specialized RNA directed DNA polymerase
that extends telomeres of eukaryotic chromosomes, has been
Fig. 1. Blocking of PAb-240 by peptides derived from human or mouse TERT and recognition of endogenous mTERT by PAb-240. A: Amino
acid sequences of the peptides used for blocking the PAb-240 antibody. The PAb-240 epitope is in bold. B: Blocking of PAb-240 by peptides
derived from human or mouse TERT. C: Western blot of endogenous mTERT.
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demonstrated to have an important role in aging, immortal-
ization and transformation. The activity of telomerase is re-
pressed in most normal human somatic tissues, whereas the
enzyme is activated during tumor progression in about 90% of
human cancers [13]. However, the mechanism of its reactiva-
tion in the process of human carcinogenesis is still unclear. It
should be noted that most normal mouse adult tissues, in
contrast to human, show detectable levels of telomerase activ-
ity [14]. Nevertheless, similarly to human, the telomerase ac-
tivity is elevated in tumors of mice [14^16]. The functional
telomerase minimally consists of the RNA subunit TR [17],
containing the template for telomere synthesis, and the cata-
lytic subunit TERT [18]. Interestingly, most tumor cells that
show telomerase activity have lost wild type p53 and usually
express mutant p53 [19,20]. Our working hypothesis was that
telomerase and mutant p53, which exhibit the common anti-
genic epitope, may share structural elements that are also
functionally related.
To con¢rm experimentally the existence of the PAb-240
epitope in the telomerase protein we measured the actual
binding of the monoclonal antibody PAb-240 to hTERT
and mTERT. In our ¢rst experiment we examined whether
peptides derived from the region containing the predicted
PAb-240 epitope in telomerase will block the binding of this
monoclonal antibody to the p53 protein. PAb-240 was prein-
cubated with equimolar amounts of the corresponding pep-
tides and then its ability to recognize p53 was examined by
Western blotting. This indirect approach was used to enable
solution contact between PAb-240 and the peptides, while
providing conformational freedom for the peptides. For the
same reason, relatively long (25 amino acids) peptides were
used. Fig. 1A,B shows that as expected, PAb-240 recognized
the baculoviral expressed p53 protein. It should be stressed
that under denaturing conditions of SDS^PAGE, the PAb-
240 epitope is exposed and detected in both wild type and
mutant p53 protein forms. Peptides derived from the sequence
of mouse TERT (No. 4) but not from human TERT (No. 2)
blocked PAb-240 binding. Peptides derived from the sequence
of mouse p53 PAb-240 epitope (Nos. 3 and 7) served as pos-
itive controls. The speci¢city of binding is demonstrated by
Table 1





20849231 RIKEN cDNA 5330403M05 [Mus musculus]
3882183 KIAA0731 protein [Homo sapiens]
10047213 KIAA1574 protein [Homo sapiens]
20540646 hypothetical protein XP_170183 [Homo sapiens]
12655205 similar to hypothetical protein FLJ10378
[Homo sapiens]
20555810 hypothetical protein XP_166331 [Homo sapiens]
8923530 hypothetical protein FLJ20559 [Homo sapiens]
6453438 hypothetical protein DKFZp727K171.1, human
(fragment) [Homo sapiens]
10434817 unnamed protein product [Homo sapiens]
10434659 unnamed protein product [Homo sapiens]
20856117 hypothetical protein XP_151622 [Mus musculus]
Immunoglobulins
13171716 immunoglobulin heavy chain variable region
[Homo sapiens]
20346796 immunoglobulin heavy chain [Mus musculus]
20860485 similar to Ig heavy chain V region VH558 A1/A4
precursor [Mus musculus]
20343054 similar to Ig H chain [Mus musculus]
20346788 similar to Ig mu chain V-D-JH1 region (B2)
precursor
20860419 similar to monoclonal antibody heavy chain
[Mus musculus]
20346794 similar to Ig H chain V-JH3 region [Mus musculus]
XM_138370 similar to AHT107 VH region [Mus musculus]
20860479 similar to Ig heavy chain V region VH558 A1/A4
precursor [Mus musculus]
20859952 similar to Ig heavy chain V region 3 precursor
[Mus musculus]
XM_111335 similar to Ig heavy chain V region 3 precursor
[Mus musculus]
20859814 similar to anti-poly(dC) monoclonal antibody heavy
chain [Mus musculus]
XM_111323 similar to Ig heavy chain V region 3 precursor
[Mus musculus]
XM_138369 similar to monoclonal antibody heavy chain
[Mus musculus]
20951123 similar to Ig heavy chain (myeloma M104E), mouse
(fragment) [Mus musculus]
XM_111348 similar to immunoglobulin heavy chain variable
region [Mus musculus]
XM_138375 similar to Ig heavy chain precursor V region
(IdB5.7), mouse (fragment) [Mus musculus]
Known function
6226781 telomerase reverse transcriptase; mTERT
[Mus musculus]
7407653 telomerase catalytic subunit [Rattus norvegicus]
20900718 mannosidase 2, K1 [Mus musculus]
18448380 transcription factor IIIA [Rattus norvegicus]
18448382 transcription factor IIIA [Mus musculus]
12849777 homolog to transcription factor IIIA [Mus musculus]
20888083 similar to carboxylesterase 2; intestinal
carboxylesterase; liver carboxylesterase-2
[Mus musculus]
20888779 similar to MBD2 (methyl-CpG-binding protein)
interacting zinc ¢nger protein; DKFZP434F162
protein [Mus musculus]
20845998 similar to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) [Mus musculus]
Fig. 2. Inhibition of telomerase activity by PAb-240. A: Telomerase
activity in M1/2 lysates after immunodepletion with PAb-240, PAb-
421 or beads only. B: Telomerase activity in H1299 lysates after
binding or immunodepletion with PAb-240 or PAb-421. The inten-
sity of the ladder pattern relative to the internal standard (faster mi-
grating band) is a measure of telomerase activity.
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the inability of mutated peptides (Nos. 5 and 6) to block PAb-
240 binding.
To test the ability of PAb-240 to bind endogenous mTERT
we performed a Western blot for mTERT using di¡erent
mouse cell lines. Two equivalent samples from each cell line
were loaded on the gel. After transfer to nitrocellulose mem-
brane, half of it was reacted with a commercial anti-TERT
antibody and the other half with PAb-240. The results shown
in Fig. 1C demonstrate that PAb-240 recognized telomerase in
cell extracts obtained from ¢broblasts derived from p53
knocked-out mice (K/O) as well as in cell extracts of p53
null early pre-B cell lines (L12 and 70Z/3). Indeed, both anti-
bodies detected similar size bands at the expected molecular
weight of 125 kDa, albeit with di¡erent a⁄nities. The stron-
gest signal evident with PAb-240 was obtained with the L12
cell line extract. With the anti-TERT antibodies, again, the
signal in L12 was the most intense. Nevertheless, a strong
signal was also evident with the other cell lines used. These
variations in the ratio of signal intensities may re£ect cell type
speci¢c post-translational modi¢cations, or polymorphism in
the sequence of mTERT protein at the PAb-240 epitope re-
gion.
In the following experiment we examined the e¡ect of PAb-
240 on the enzymatic activity of telomerase as measured by
the TRAP assay. Cell extracts were incubated with PAb-240
or with another anti-p53 antibody, PAb-421, which served as
a negative control. This antibody recognizes the C-terminal
epitope of p53, consisting of amino acids 371^380 [21]. Since
the mere binding of PAb-240 and telomerase might not nec-
essarily interfere with telomerase enzymatic activity, we also
performed immunodepletion of the cell lysates with protein A
beads to physically remove the complex from the solution. To
avoid potential multiprotein complexes, which would pose
problems in interpreting the results, all the cell lines used in
these experiments were p53 negative.
As seen in Fig. 2A, a signi¢cant inhibition of telomerase
activity by immunodepletion with PAb-240 in the M1/2 mouse
myeloid cell line was observed. Interestingly, an even more
striking inhibition was evident in human H1299 cells not
only in the case of immunodepletion but also by the mere
addition of PAb-240 (Fig. 2B). The speci¢city of the inhibi-
tion is demonstrated by the lack of e¡ect of PAb-421 anti-
body.
In summary, our results show that PAb-240 binds to the
linear epitope of the mTERT catalytic subunit. Of note is the
fact that PAb-240 does not recognize human TERT in either
native or denatured conformation. Nevertheless, telomerase
activity of H1299 cells is strongly inhibited by PAb-240.
One intriguing possibility is that PAb-240 binds to and inac-
tivates some other protein(s), which are necessary for telomer-
ase activity. The existence of a common epitope between mu-
tant p53 and telomerase may suggest that the two proteins
contribute to malignant transformation through a common
pathway. Furthermore, our search yielded a number of addi-
tional human proteins with yet unknown functions containing
this epitope that may be associated with the same biological
pathway.
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